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Abstract
This phase 2, double-blind, placebo-controlled, hypothesis-generating study evaluated the effects of oral reldesemtiv, a fast
skeletal muscle troponin activator, in patients with spinal muscular atrophy (SMA). Patients ≥ 12 years of age with type II, III,
or IV SMA were randomized into 2 sequential, ascending reldesemtiv dosing cohorts (cohort 1: 150 mg bid or placebo [2:1];
cohort 2: 450 mg bid or placebo [2:1]). The primary objective was to determine potential pharmacodynamic effects of reldesemtiv
on 8 outcome measures in SMA, including 6-minute walk distance (6MWD) and maximum expiratory pressure (MEP). Changes
from baseline to weeks 4 and 8 were determined. Pharmacokinetics and safety were also evaluated. Patients were randomized to
reldesemtiv 150 mg, 450 mg, or placebo (24, 20, and 26, respectively). The change from baseline in 6MWD was greater for
reldesemtiv 450 mg than for placebo at weeks 4 and 8 (least squares [LS] mean difference, 35.6 m [p = 0.0037] and 24.9 m [p =
0.058], respectively). Changes from baseline in MEP at week 8 on reldesemtiv 150 and 450 mg were significantly greater than
those on placebo (LS mean differences, 11.7 [p = 0.038] and 13.2 cm H2O [p = 0.03], respectively). For 6MWD and MEP,
significant changes from placebo were seen in the highest reldesemtiv peak plasma concentration quartile (Cmax > 3.29 μg/mL;
LS mean differences, 43.3 m [p = 0.010] and 28.8 cm H2O [p = 0.0002], respectively). Both dose levels of reldesemtiv were well
tolerated. Results suggest reldesemtiv may offer clinical benefit and support evaluation in larger SMA patient populations.
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Introduction
Spinal muscular atrophy (SMA) is a genetic neuromuscular
disease in which reduced amounts of functional survival motor neuron (SMN) protein result in progressive muscle weakness and atrophy, leading to various degrees of functional
motor impairment [1]. Analyses of markers of muscle involvement, including contractile and regulatory proteins, suggest a delay in muscle maturation in samples from patients
with SMA compared to controls [2, 3]. Magnetic resonance
imaging of muscle in children and adults aged 2 to 45 years
with SMA type II and III showed differences with varying
degrees of proximal to distal gradient, but found some muscle
groups were always spared and muscles involved demonstrated atrophy in both SMA types [4].
Although SMA has historically been classified based on
age of onset and highest level of motor function achieved
[1], in the advent of recently approved therapies, this classification system has become less relevant. All three recently
approved SMA course-modifying treatments increase motor
neuron SMN protein content. Nusinersen, an antisense oligonucleotide drug that increases SMN production by altering
SMN2 splicing [5, 6], was the first approved medication for
the specific treatment of SMA. The beneficial effects of
nusinersen in infants and children are well substantiated
[5–8], but currently there are limited data available from older
patients; findings for nusinersen in adults are limited to observational studies rather than controlled clinical trials [9, 10].
The gene therapy onasemnogene abeparvovec-xioi is effective in infants and recently gained approval by the US Food
and Drug Administration for patients < 2 years of age with
SMA [11, 12]. In addition, risdiplam, a small molecule
SMN2 splicing modifier, is also now approved to treat patients
2 months and older with SMA, and has been studied in a
randomized, double-blind, placebo-controlled study in patients up to the age of 25 [13, 14]. Even after treatment with
these new therapies, many very young SMA patients fail to
meet age-specific motor milestones, and treatment later in the
course of disease results in even less dramatic benefits.
Therefore, there continue to be unmet medical needs despite
these dramatic advances, particularly regarding persistent weakness, impaired endurance, and fatigue [8, 12]. As new emerging
treatments for SMA impact the development of motor milestones,
and as treatment before manifestation of symptoms may be possible through newborn screening, the clinical features of SMA are
likely to slowly evolve. Other features such as SMN2 copy number, and age of onset of signs and symptoms may also impact
clinical course [15, 16], but even as the clinical landscape of
SMA evolves, the vast majority of patients will continue to experience weakness and fatigue.
Reldesemtiv (CK-2127107) is being developed to improve
skeletal muscle function for disease states involving muscle weakness or fatigue; it selectively binds to the fast skeletal troponin

complex and sensitizes it to calcium [17]. In a double-blind, randomized, placebo-controlled, phase 1 clinical study in healthy participants, fibular nerve stimulation at sub-tetanic frequencies resulted in significantly increased placebo-corrected changes in the force
generated by the tibialis anterior muscle in a dose-, concentration-,
and frequency-dependent manner following reldesemtiv treatment.
In this and 2 additional double-blind, randomized, placebo-controlled, phase 1 studies, reldesemtiv was well tolerated at singledose levels from 30 to 4000 mg and multiple doses of 300 and
500 mg twice daily (bid) [18]. Adverse events (AEs) observed in
≥ 10% of patients in at least one of the studies included headache,
dizziness, nausea, and asthenopia (eye strain); all AEs were mild or
moderate in severity. No meaningful differences in pharmacokinetic (PK) parameters were found between young and elderly
volunteers.
We conducted a hypothesis-generating, phase 2 study with no
pre-specified primary outcome measure that tested a number of
pharmacodynamic (PD) outcomes. Two oral dose levels (150
and 450 mg bid) of reldesemtiv were evaluated in patients with
SMA. Secondary objectives were to evaluate the safety and tolerability of reldesemtiv as well as its PK properties.

Methods
Study Design
The study was a phase 2, double-blind, randomized, placebocontrolled, multiple-dose investigation of reldesemtiv in 2 sequential ascending dose cohorts of patients with SMA
(ClinicalTrials.gov identifier NCT02644668), conducted from
December 2015 through May 2018 at 18 centers in Canada and
the USA. The study received approval from institutional review
boards before commencing, and was conducted in compliance
with good clinical practice and the Declaration of Helsinki;
written informed consent was obtained from patients
≥ 18 years of age, and parental permission and child assent
were obtained for those < 18 years of age. Patients were
randomized via an interactive web response system to receive
reldesemtiv 150 mg bid or placebo (2:1; cohort 1), or
reldesemtiv 450 mg bid or placebo (2:1; cohort 2), stratified
by ambulatory status. The study drug was constituted with
water at the site; the suspension was given to the patient for
oral administration (9 mL) bid, approximately every 12 h after a
≥ 3-h fast, with a 1-h fast following dosing, for a total of
8 weeks.

Study Participants
Patients eligible for enrollment had genetically confirmed diagnosis of type II, III, or IV SMA and were ≥ 12 years of age.
Ambulatory patients, after independently achieving a standing
position, were required to complete at least 1 lap (≥ 50 m) in
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the 6-minute walk test (6MWT) without assistance. Nonambulatory patients needed to be able to tolerate an upright
supported sitting position continuously for 3 h, and required a
wheelchair for mobility needs, though they may have been
able to stand or walk less than 50 m without assistance in
6 min. Patients were also required to have forced vital capacity
(FVC) > 20% predicted, Hammersmith Functional Motor
Scale Expanded (HFMSE) score ≥ 10 and ≤ 54, and contracture of elbow flexion ≤ 90 degrees. Patients must have been
able to swallow an oral suspension and were expected to be
able to continue to do so for the duration of the study. Prior or
concomitant treatment with nusinersen was not allowed.

Outcome Measures
Outcome measures were assessed at screening, day 1, at the
end of weeks 1, 2, 4, and 8, and at follow-up (4 weeks after the
last dose) for all except timed up and go (TUG) and 6MWT,
which were assessed at screening, day 1, at the end of weeks 4
and 8, and at follow-up. The Spinal Muscular Atrophy-Health
Index (SMA-HI) was completed on day 1 and at the end of
week 8 in cohort 2 only. All clinical measures were standardized with certified clinical evaluators who underwent appropriate training to ensure consistency of measures across all
sites and visits throughout the study.
Pulmonary function was assessed via FVC, as well as maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP), measured using calibrated spirometers by Micro
Direct, Inc., Lewiston, ME (FVC: MicroLab Spirometer MK8;
MIP and MEP: MicroRPM). Isometric muscle strength was
assessed bilaterally using a make test, in which the examiner
holds the dynamometer in a set position as the patient pushes
against it, for 3 muscle groups (elbow flexion, knee flexion, and
shoulder abduction) with a MicroFET2 handheld dynamometer
(HHD, Hoggan Scientific, LLC, Salt Lake City, UT). The maximum muscle strength of 2 measurements was reported as percent change from baseline, with imputed muscle strength set to
missing if the baseline value was 0. The mega-score, a composite
score for strength across the 3 muscle groups, was calculated as
the mean of transformed muscle strength scores. The HFMSE
was used to evaluate functional mobility with a scale score ranging from 0 to 66, with higher scores reflecting better function
[19]. The revised upper limb module (RULM) was designed to
be used in conjunction with the HFMSE; it tests upper limb
function based on reachable workspaces from upper (shoulder),
middle (elbow), and distal (wrist and hand) regions of the upper
limb with a range of scoring from 0 to 44, with higher scores
reflecting greater function [20].
The 6MWT, performed in ambulatory patients, measured the
distance a patient walked in 6 min (6MWD) in order to assess
functional endurance capacity and mobility; fatigue was measured by the difference in distance walked between the first and
last minutes [21]. To assess mobility, balance, and walking

ability, the TUG, performed in ambulatory patients, measured
the time for a patient to rise from a chair, traverse 3 m, turn
around, return to the chair, and sit down [22]. Patient-reported
SMA burden was measured using the SMA-HI questionnaire,
with higher scores reflecting greater burden of disease; this was
performed only in cohort 2 given the timing of when the questionnaire was fully developed [23]. Safety was assessed by monitoring AEs, coded using the Medical Dictionary for Regulatory
Activities (MedDRA), version 18.0, clinical laboratory findings,
and electrocardiogram intervals.
For PK endpoints, blood samples for determination of plasma
concentrations of reldesemtiv were collected prior to dosing on
day 1 and at the ends of weeks 1, 2, 4, and 8. Concentrations
were determined by a validated solid-phase extraction method
using high-performance liquid chromatography followed by tandem mass spectrometric detection.

Statistical Analysis
The safety population consisted of all patients who received ≥ 1
dose of study drug, whereas the PD population included patients
in the safety population with ≥ 1 post-baseline endpoint assessment, and the PK population included those in the safety population with ≥ 1 evaluable PK level. Baseline characteristics and
safety data were summarized descriptively overall and by treatment, dose level, and ambulatory status in the safety population.
For dose-response PD effects, the change from baseline in a
continuous endpoint was analyzed by repeated measures mixed
effect models that accounted for within-patient correlation with
an unstructured covariance matrix or compound symmetry when
an unstructured covariance matrix could not converge. The covariates included dose level, visit, interaction between dose level
and visit, ambulatory status, and the baseline value of the variable
being analyzed (except for muscle strength mega-score, for
which the score itself represents a percent change from baseline).
Ambulatory status was removed from the model for subgroup
analyses by ambulatory status. Important baseline characteristics
(including age, gender, and age of disease onset) were also examined and included in the model.
The slope of change from baseline for continuous endpoints was analyzed by a mixed effect model with no intercept, and included dose level, days from the first dose of study
treatment as a random covariate, interaction of dose level-bydays from the first dose of study treatment, ambulatory status,
and baseline value of the variable being analyzed.
Maximum observed plasma concentration (Cmax), predose
plasma concentration (Ctrough), and area under the plasma
concentration-time curve from 0 to 12 h (AUC0–12) were calculated based on the plasma concentrations of reldesemtiv
using noncompartmental PK methods and were summarized
descriptively. For concentration-response PK analyses, the
change in continuous endpoints from baseline was analyzed
by a mixed effect model that accounted for within-patient
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Table 1 Baseline demographics,
disease characteristics, and
pharmacodynamic measures

Placebo

Reldesemtiv 150 mg
bid

Reldesemtiv 450 mg
bid

(n=24)

(n=20)

28.5 (16.0)
8 (30.8)
15 (57.7)
22 (84.6)
24.3 (7.4)
2 (7.7)
24 (92.3)
3.8 (4.6)

27.8 (12.0)
7 (29.2)
14 (58.3)
23 (95.8)
25.4 (9.2)
3 (12.5)
21 (87.5)
7.8 (6.9)

32.6 (17.9)
5 (25.0)
12 (60.0)
18 (90.0)
25.1 (5.5)
1 (5.0)
19 (95.0)
8.1 (9.4)

29.4 (15.3)
20 (28.6)
41 (58.6)
63 (90.0)
24.9 (7.5)
6 (8.6)
64 (91.4)
6.4 (7.2)

11 (42.3)
84.4 (22.4)

12 (50.0)
83.1 (22.0)

8 (40.0)
85.9 (21.2)

31 (44.3)
84.4 (21.7)

86.5 (36.9)
−105.7
(38.5)
30.6 (16.6)
31.0 (8.7)

94.0 (43.4)
−109.1 (44.2)

88.9 (47.7)
−101.0 (43.2)

36.0 (17.2)
34.8 (7.9)

30.4 (16.3)
33.7 (8.0)

89.8 (41.8)
−105.6
(41.3)
32.4 (16.7)
33.1 (8.3)

21.5 (11.0)
240.1
(111.8)
33.1 (19.9)

15.7 (6.5)
316.6 (69.0)

22.8 (16.1)
311.0 (107.3)

19.2 (10.3)
287.3 (99.2)

NA

39.8 (17.1)

37.5 (18.1)

(n=26)

Age, years, mean (SD)
Age<18 years, n (%)
Male, n (%)
White, n (%)
BMI, mean (SD)
SMA type II, n (%)
SMA type III, n (%)
Age at SMA onset, years,
mean (SD)
Ambulatory, n (%)
% predicted FVC, mean
(SD)
MEP, cm H2O, mean (SD)
MIP, cm H2O, mean (SD)
HFMSE score, mean (SD)
RULM total score, mean
(SD)
TUG, s, mean (SD)
6MWD, m, mean (SD)
SMA-HI total score,
mean (SD)a
a

Overall
(n=70)

SMA-HI was only performed in participants in cohort 2

6MWD 6-minute walking distance, BMI body mass index, bid twice daily, FVC forced vital capacity, HFMS-E
Hammersmith Functional Motor Score-Expanded, MEP maximum expiratory pressure, MIP maximum inspiratory pressure, NA not assessed, RULM revised upper limb module, SD standard deviation, SMA-HI Spinal
Muscular Atrophy-Health Index, TUG timed up and go

correlation with an unstructured covariance matrix. The covariates included PK parameter, visit, interaction between visit and the PK parameter, ambulatory status, and the baseline
value of the variable being analyzed.
For model-based PD analyses, least squares (LS) mean,
difference of LS means between reldesemtiv and placebo
(combined from the 2 cohorts), their standard errors (SEs)
and 95% confidence intervals (CIs), and 2-sided p values were
determined. Multiplicity was not addressed in this hypothesisgenerating study; all p values of statistical significance are
nominal.

Results

to reldesemtiv, 41 (93.2%) completed the 8-week study. Three
patients (6.8%), all in the 450 mg group, discontinued treatment early due to an AE, a protocol violation, or withdrawal
by the patient; the latter 2 also withdrew from the study.
Twenty-four of the 26 patients (92.3%) in the placebo group
completed the study; 2 patients (7.7%) discontinued treatment
early due to an AE but completed the planned visits for those
who terminated from treatment early. One additional patient
completed dosing but was lost to follow-up and did not complete the final follow-up study visit.
Baseline demographics and PD measures were generally similar across treatment groups (Table 1). The overall mean age was
29.4 years (range 12–72 years), and the majority of patients were
male (58.6%) and white (90.0%). Most (91.4%) patients had type
III SMA (none had type IV); 44.3% were ambulatory.

Patient Disposition and Baseline Characteristics
Outcomes
Seventy patients were randomized to placebo (n = 26),
reldesemtiv 150 mg bid (n = 24), or reldesemtiv 450 mg bid
(n = 20) (Supplemental Fig. 1). Of the 44 patients randomized

Changes from baseline to week 8 for most of the PD parameters were not significantly different from placebo in either
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Fig. 1 Least squares mean
change in outcome measures from
baseline to week 8 in participants
receiving reldesemtiv at doses of
(A) 150 mg bid, and (B) 450 mg
bid compared with placebo.
*LSM change on reldesemtiv minus LSM change on placebo for
all measures except TUG and
SMA-HI, which are LSM change
on placebo minus LSM change on
reldesemtiv. bid = twice daily;
FVC = forced vital capacity;
HFMS-E = Hammersmith
Functional Motor ScoreExpanded; LSM = least squares
mean; MEP = maximum expiratory pressure; MIP = maximum
inspiratory pressure; pbo = placebo; RULM = revised upper limb
module; SMA-HI = Spinal
Muscular Atrophy-Health Index;
TUG = timed up and go

A
% Predicted FVC

Change from baseline at week 8 (150 mg bid vs. placebo)*
No. of Patients
(placebo/reldesemtiv)
26/24

LSM Difference
(reldesemtiv-pbo)

Estimate

p Value

−1.14

0.44

MIP

26/24

2.94

0.54

MEP

26/24

11.69

0.038

Muscle mega-score

26/24

−4.59

0.55

HFMS-E

26/24

−0.38

0.68

RULM

26/24

0.61

0.29

6-minute walk

11/12

7.72

0.47

Timed up and go

9/10

0.78

0.76

Favors Placebo

−40

B
% Predicted FVC

−20

Favors Treatment

0

20

40

Change from baseline at week 8 (450 mg bid vs. placebo)*
No. of Patients
(placebo/reldesemtiv)
26/19

LSM Difference
(reldesemtiv-pbo)

Estimate

p Value

−2.04

0.20
0.85

MIP

26/19

−0.99

MEP

26/19

13.15

0.03

Muscle mega-score

26/19

−15.2

0.067

HFMS-E

26/19

−1.00

0.31

RULM

26/19

−0.12

0.85

11/7

24.89

0.058

9/4

3.10

0.35

10/19

0.93

0.83

6-minute walk
Timed up and go
SMA-HI

Favors Placebo

−40

reldesemtiv dose group with the exception of the 6MWT and
MEP (Fig. 1).
The 6MWD increased in both the reldesemtiv 150-mg and
450-mg dose groups at weeks 4 and 8 and was fairly stable in
the placebo arm (Fig. 2(A)). The LS mean difference was
significantly greater than placebo at week 4 for the reldesemtiv
450 mg bid group (35.63 m, p = 0.0037); at week 8, the difference was 24.89 m (p = 0.058). A nominally significant LS
mean difference of 30.8 m (p = 0.038) between reldesemtiv
450 mg bid and placebo was observed up to 4 weeks after
dosing at the follow-up visit. Older age appeared to be related
to larger increases in 6MWD from baseline to week 8 (p =
0.058). A waterfall plot of individual changes from baseline to
week 8 demonstrates that 13 of the 18 reldesemtiv-treated
patients and 5 of the 9 placebo-treated patients had some improvement in 6MWD (Fig. 2(B)); of the 5 patients with the
greatest improvement, 4 were on reldesemtiv.
MEP showed significant LS mean differences versus placebo for reldesemtiv 150 mg bid (11.69 cm H2O, p = 0.038,
Fig. 1(A)) and for reldesemtiv 450 mg bid (13.15 cm H2O,
p = 0.03, Fig. 1(B)). A lower baseline MEP appeared to be
related to a larger increase in MEP from baseline to week 8
(p = 0.062). Waterfall plots of individual changes from baseline to week 8 in MEP by ambulatory status show that responses to reldesemtiv were observed in both ambulatory

−20

Favors Treatment

0

20

40

and non-ambulatory patients (Fig. 3(A, B)). In addition, baseline values in the non-ambulatory patients were lower, whereas the ambulatory patients with higher values may have been
limited by a ceiling effect.
Responses to the SMA-HI questionnaire to measure patientreported burden at 8 weeks showed no difference between the
reldesemtiv 450 mg and placebo groups (p = 0.83, Fig. 1(B)).

Pharmacokinetics
Plasma concentrations of reldesemtiv increased by dose (Fig. 4).
Within each dose group, plasma concentrations at weeks 2 and 8
were similar. Assessment of PK parameters at week 8 showed
dose-dependent increases in Cmax and drug exposure (Table 2).
Pharmacodynamic Response in Relation to Pharmacokinetics
Individual changes from baseline to week 8 in 6MWD by Cmax
were examined (Fig. 5(A)). The slope of the line shows that the
6MWD increased as Cmax increased (p = 0.0086). When examined by quartiles of Cmax, statistically significant and clinically
meaningful changes from baseline to week 8 were observed in
the highest quartile of Cmax (> 3.29 μg/mL) for MEP (p =
0.0002) and 6MWD (p = 0.010) (Fig. 5(B)).
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A
LSM (± SEM) of change
in 6MWD from baseline (m)

Fig. 2 (A) Changes from baseline
in 6MWD over time and (B) waterfall plot of individual changes
from baseline to week 8 in
6MWD. 6MWD = 6-minute
walking distance; bid = twice
daily; LSM = least squares mean;
m = meters; SEM = standard error
of the mean

p = 0.0037

40

p = 0.058

p = 0.038

34
28
22
16

p = 0.25

p = 0.47

p = 0.33

10
4
−2
−8
Baseline

Week 4

Week 8

Follow-up

Visit
Placebo

B

150 mg bid

450 mg bid

Change from baseline
in 6MWD at week 8 (m)

80
60
40
20
0
−20
−40
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Patient
Placebo

450 mg bid

Change from baseline
in MEP at week 8 (cm H 20)

A
20
0
−20
−40
−60
−80
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38

Patient
Placebo

150 mg bid

450 mg bid

B
100

Change from baseline
in MEP at week 8 (cm H 20)

Fig. 3 Waterfall plots of
individual changes in MEP from
baseline to week 8 in (A) ambulatory and (B) non-ambulatory
patients. MEP = maximum expiratory pressure; bid = twice daily

150 mg bid

50

0

−50

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Patient
Placebo

150 mg bid

450 mg bid
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Table 2 Summary of
pharmacokinetic parameters for
each dose of reldesemtiv at week 8

Parameter, geometric mean (geometric % CV)

Cmax, μg/mL
Ctrough, μg/mL
AUC0–12, h×μg/mL
a

Reldesemtiv 150 mg bid

Reldesemtiv 450 mg bid

(n=23)

(n=15)a

1.40 (43.18)
0.34 (88.27)
9.00 (49.38)

3.34 (48.77)
0.94 (98.06)
25 (52.19)

For Ctrough, n = 17

AUC0–12 area under the plasma concentration curve from 0 to 12 h, bid twice daily, Cmax maximum observed
plasma concentration, Ctrough predose plasma concentration, CV coefficient of variation

Safety
AEs were reported in 92.3%, 83.3%, and 85.0% of patients in
the placebo, reldesemtiv 150 mg bid, and reldesemtiv 450 mg
bid groups, respectively (Table 3). Most AEs were mild or
moderate in severity. The most frequently reported AEs in
the placebo and combined reldesemtiv groups were headache
(19.2% and 25.0%), nausea (19.2% and 11.4%), and fatigue
(15.4% and 9.1%, respectively).
Investigator-assessed serious AEs (SAEs) were reported
for 3 patients: 2 in the reldesemtiv 150 mg bid group (gastroenteritis Escherichia coli, gastroenteritis Salmonella, and
myocarditis in 1 patient and facial pain and hypesthesia for
the other) and 1 in the reldesemtiv 450 mg bid group (traumatic fracture). The sponsor also upgraded the AEs of another
patient in the reldesemtiv 450 mg bid group to SAEs (serum
aspartate aminotransferase and creatine kinase increased). All
SAEs resolved and none were considered to be related to the
study drug. Two patients in the placebo group and 1 in the
reldesemtiv 450 mg bid group reported AEs that led to early
treatment termination (Table 3); all were considered by the
treating investigator to be related to the study drug. No deaths
were reported during the study.

Discussion
In this hypothesis-generating study, 6MWD and MEP improved
versus placebo in patients with SMA receiving reldesemtiv, consistent with increased skeletal muscle force production by
Day 1
Mean concentration of
reldesemtiv (µg/mL)

Fig. 4 Plasma concentrations of
reldesemtiv over time. Error bars
represent standard errors. bid =
twice daily

reldesemtiv. The LS mean change from baseline in the 6MWD
at week 4 was significantly greater for reldesemtiv 450 mg bid
compared with placebo, and difference at week 8 trended to
conventional statistical significance. There was a persistent effect
in the 6MWD 4 weeks after the last dose; a similar persistent
benefit in slow vital capacity was also observed in the
FORTITUDE-ALS phase 2 trial of reldesemtiv in amyotrophic
lateral sclerosis (ALS) patients [24], and in a phase 2 ALS trial
with tirasemtiv, a first-generation fast skeletal muscle activator
[25]. MEP measurements, which reflect expiratory muscle
strength, demonstrated a nominal increase at week 8 for both
reldesemtiv treatment groups compared with placebo. Changes
seen in MEP but not in FVC may be related to the well-known
relative preservation of the diaphragm compared to other ventilatory muscles in SMA [26]. Significant changes from placebo at
week 8 were seen in 6MWD and MEP in the highest quartiles of
Cmax for reldesemtiv. These results are consistent with those from
phase 1 studies of reldesemtiv in healthy volunteers in which
significant dose- and frequency-dependent increases were observed in the peak force of tibialis anterior muscle contraction
after deep fibular nerve stimulation following treatment with
reldesemtiv [18].
As adult SMA patients have historically not been included in most interventional SMA trials, this trial offers
insights into the challenges encountered with the commonly used SMA outcome measures in this older patient
population. Because reldesemtiv is known to increase
skeletal muscle force in response to neural input, outcome
measures specific to fatigue and muscle force may be
more sensitive to changes due to treatment. The HFMSE
Week 2
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A
Change from
baseline to week 8 in 6MWD

Fig. 5 (A) Individual changes
from baseline to week 8 in
6MWD by Cmax, and (B) changes
from baseline to week 8 in MEP
and 6MWD by quartiles of Cmax.
*Difference between placebo and
reldesemtiv. 6MWD = 6-minute
walking distance; Cmax = maximum observed plasma concentration; LSM = least squares mean;
MEP = maximum expiratory
pressure; pbo = placebo
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was developed for children with SMA, and includes
crawling and arising from the floor, which are infrequently performed by adults, resulting in their assessment being
impacted by a motor learning effect in addition to weakness from SMA. The HFMSE also includes no timed
tests, so is insensitive to changes in stamina or fatigue.
More sensitive outcome measures are needed to address
these domains that have been reported as important to the
adult SMA patient population. Potential alternatives to the
HFMSE include the Revised Hammersmith (RHS) and
Motor Function Measurement 32 (MFM-32) assessments.
The RHS includes 2 timed tests, though it still includes
crawling and kneeling. Testing has been done in the RHS
for a small number of patients over the age of 14 [27].
The MFM-32 was developed for use in patients aged 6 to
60 years and does not require the patient to kneel or
crawl. It has the additional benefit of having the items
classified into 3 domains: D1 for standing and transfers,
D2 for axial and proximal motor function and D3 for
distal motor function. In an ambulatory patient population, D1 items are likely to be most impacted, whereas
D2 may or may not be abnormal depending on the degree
of their limb and trunk weakness. This permits response
to an intervention to be measured both for the overall

0

50

MFM-32 score as well as the scores of the individual
domains [28–30].
The SMA-HI questionnaire was used to assess patientreported disease burden as an exploratory outcome. No difference was observed between reldesemtiv and placebo treatment
groups at week 8. The SMA-HI was added to the protocol for
the second cohort only. Because some sites were delayed in
getting approval for the revised protocol and consent form,
only 19 patients filled out the SMA-HI, limiting the ability
to draw meaningful conclusions from this initial investigation,
though a patient-reported outcome measure will clearly be of
value for treatment of unmet needs in this patient population.
PK exposures in this study were below levels that were
well tolerated and associated with increased PD activity compared to placebo in the phase 1 studies (that used a different
drug formulation). The reldesemtiv dose levels tested here,
150 mg and 450 mg administered twice daily, were also well
tolerated and associated with increased PD activity compared
with placebo treatment. The AEs reported were generally similar to those in the placebo group and were consistent with
those observed in phase 1 studies of reldesemtiv [18]. The
good tolerability of these dose levels, as well as no evidence
of an efficacy plateau in this trial, and the prior safety and
tolerability of higher exposures that generated even larger

Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Table 3 Adverse events reported
in ≥ 2 patients treated with
reldesemtiv

Preferred terma, n (%)

Placebo

Reldesemtiv
150 mg bid

Reldesemtiv
450 mg bid

All
reldesemtiv

(n=24)

(n=20)

(n=44)

24

20 (83.3)

17 (85.0)

37 (84.1)

(92.3)
5 (19.2)
5 (19.2)
4 (15.4)
3 (11.5)
3 (11.5)
4 (15.4)
0
2 (7.7)
1 (3.8)
0

6 (25.0)
3 (12.5)
2 (8.3)
1 (4.2)
3 (12.5)
0
3 (12.5)
2 (8.3)
2 (8.3)
2 (8.3)

5 (25.0)
2 (10.0)
2 (10.0)
1 (5.0)
0
2 (10.0)
2 (10.0)
1 (5.0)
0
1 (5.0)

11 (25.0)
5 (11.4)
4 (9.1)
2 (4.5)
3 (6.8)
2 (4.5)
5 (11.4)
3 (6.8)
2 (4.5)
3 (6.8)

Contusion
Respiratory tract congestion
Serum creatine kinase increased
Skin abrasion
Decreased appetite
Hypoesthesia
Respiratory tract infection
Patients with AEs resulting in early
treatment termination
Serum creatine kinase increased
Asthenia

0
0
0
0
1 (3.8)
0
0
2 (7.7)

2 (8.3)
2 (8.3)
0
0
1 (4.2)
1 (4.2)
1 (4.2)
0

0
0
2 (10.0)
2 (10.0)
1 (5.0)
1 (5.0)
1 (5.0)
1 (5.0)

2 (4.5)
2 (4.5)
2 (4.5)
2 (4.5)
2 (4.5)
2 (4.5)
2 (4.5)
1 (2.3)

0
1 (3.9)

0
0

1 (5.0)
0

1 (2.3)
0

Gait disturbance
Muscular weakness

1 (3.9)
1 (3.9)

0
0

0
0

0
0

(n=26)

Patients with AEs

Headache
Nausea
Fatigue
Fall
Nasopharyngitis
Upper respiratory tract infection
Constipation
Diarrhea
Abdominal pain upper
Dyspepsia

a

Medical Dictionary for Regulatory Activities (version 18.0)

AE adverse event

PD effects in the PD study provide a rationale to study higher
dose levels in an effort to increase exposures.
The small population size and relatively short treatment
period are limitations of this study. In addition, the results
for MEP at 8 weeks were nominally statistically significant
for both doses of reldesemtiv compared to placebo; for the
6MWD, only the higher dose of reldesemtiv was nominally
statistically significant compared to placebo at 4 weeks and
trended towards significance at 8 weeks. In a post hoc analysis
of baseline features, a trend to predicting a response in MEP
was limited to a lower baseline MEP value and only older age
showed a trend to predicting a response in the 6MWD.
However, the purpose of this trial was to generate hypotheses to test in future studies and so it had no predetermined
clinical primary endpoint. Good tolerability and the observation that 6MWD and MEP increased with plasma concentrations support future studies of reldesemtiv in larger populations of individuals with SMA. As reldesemtiv has a distinctly
different mechanism of action compared to currently available

therapies for SMA that increase levels of the SMN protein, in
a future reldesemtiv trial, we anticipate including eligibility
criteria permitting current or past use of such medicines with
enrolled patients stratified accordingly. In conclusion, we believe the promising effects of reldesemtiv on 6MWD and
MEP, in association with tolerability of the doses employed
in this trial, support further clinical development of
reldesemtiv for the potential treatment of patients with SMA.
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